Dr. David Eric Gerber, MD

Dr. Gerber practices at William P. Clements Jr. University Hospital in Dallas, Texas, part of The University of Texas System.

Dr. Gerber's NPI, 1336295039, was assigned on January 26, 2007. Dr. Gerber graduated from Weill Cornell Medicine in 2000. Dr. Gerber holds Texas license L3654.

Dr. Gerber's primary practice is William P. Clements Jr. University Hospital, at 6201 Harry Hines Blvd, Dallas, TX 75390 in Dallas County. The practice phone is (214) 633-5555.

Dr. Gerber's primary practice is William P. Clements Jr. University Hospital in Dallas, Texas, part of The University of Texas System. Dr. Gerber is also affiliated with Parkland Memorial Hospital. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Dr. Gerber to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gerber practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Gerber's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Gerber is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Gerber's licenses on file in 2 states: Texas and Maryland.

Dmand AI lists lung cancer among the conditions Dr. Gerber treats.

CMS data shows 225 Medicare services from Dr. Gerber across 2 procedure codes in 2024, all of them office visits, for 76 Medicare patients. Medicare paid $21,523 for them.

CMS counts 76 Medicare patients who saw Dr. Gerber in 2024. The largest group is 65 to 74, with 33 patients. 75% of them have cancer, and 74% have high cholesterol. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gerber's median patient age at 66, with 52% women.

In 2024, Dr. Gerber wrote 243 Medicare Part D claims for 48 patients. 66% of them were for generic drugs. CMS names the drug for 142 of them, across 8 drugs with 11 or more claims each, at $621,156 in total drug cost. In 2023, CMS named 177 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Gerber for performance year 2024, reported as part of a group. Dr. Gerber accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 281 papers to Dr. Gerber, published from 2006 to 2025. 2019 was the busiest year, with 27. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Gerber has published most often in Lung Cancer. Dr. Gerber's most frequent co-authors are John Dorrance Minna, MD, David Gerber, MD and Sawsan Rashdan, MD.

Dmand AI links Dr. Gerber to 9 clinical trials, 3 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Carcinoma, Small Cell. University of Texas Southwestern Medical Center sponsors the most, 2.

CMS Open Payments shows 84 general payments to Dr. Gerber from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 53% of the total. Bristol-Myers Squibb Company paid the most, $35,483.

Dmand AI lists 1 award for Dr. Gerber, most recently CMS Stage 1 EHR in 2012.

Dr. Gerber graduated from Weill Cornell Medicine in 2000. Dr. Gerber is a member of ASCO.

Dr. Gerber is in network with 21 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 13. Check the plan with the practice before a visit.